TY - JOUR
T1 - Progress in the mechanism of neuronal surface P antigen modulating hippocampal function and implications for autoimmune brain disease
AU - Barake, Francisca
AU - Bravo-Zehnder, Marcela
AU - González, Alfonso
N1 - Funding Information:
A.G. receives research funding from the ‘Financiamiento Basal para Centros Científicos y Tecnológicos de Excelencia de ANID’ through the ‘Centro Ciencia y Vida: ANID/FB210008’ and the ‘Centro de Envejecimiento y Regeneración: #ACE210009’.
Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.
PY - 2022/6/1
Y1 - 2022/6/1
N2 - Purpose of reviewThe aim of this study was to present a new regulation system in the hippocampus constituted by the neuronal surface P antigen (NSPA) and the tyrosine phosphatase PTPMEG/PTPN4, which provides mechanistic and therapeutic possibilities for cognitive dysfunction driven by antiribosomal P protein autoantibodies in patients with systemic lupus erythematosus (SLE).Recent findingsMice models lacking the function of NSPA as an E3 ubiquitin ligase show impaired glutamatergic synaptic plasticity, decreased levels of NMDAR at the postsynaptic density in hippocampus and memory deficits. The levels of PTPMEG/PTPN4 are increased due to lower ubiquitination and proteasomal degradation, resulting in dephosphorylation of tyrosines that control endocytosis in GluN2 NMDAR subunits. Adult hippocampal neurogenesis (AHN) that normally contributes to memory processes is also defective in the absence of NSPA.SummaryNSPA function is crucial in memory processes controlling the stability of NMDAR at PSD through the ubiquitination of PTPMEG/PTPN4 and also through AHN. As anti-P autoantibodies reproduce the impairments of glutamatergic transmission, plasticity and memory performance seen in the absence of NSPA, it might be expected to perturb the NSPA/PTPMEG/PTPN4 pathway leading to hypofunction of NMDAR. This neuropathogenic mechanism contrasts with that of anti-NMDAR antibodies also involved in lupus cognitive dysfunction. Testing this hypothesis might open new therapeutic possibilities for cognitive dysfunction in SLE patients bearing anti-P autoantibodies.
AB - Purpose of reviewThe aim of this study was to present a new regulation system in the hippocampus constituted by the neuronal surface P antigen (NSPA) and the tyrosine phosphatase PTPMEG/PTPN4, which provides mechanistic and therapeutic possibilities for cognitive dysfunction driven by antiribosomal P protein autoantibodies in patients with systemic lupus erythematosus (SLE).Recent findingsMice models lacking the function of NSPA as an E3 ubiquitin ligase show impaired glutamatergic synaptic plasticity, decreased levels of NMDAR at the postsynaptic density in hippocampus and memory deficits. The levels of PTPMEG/PTPN4 are increased due to lower ubiquitination and proteasomal degradation, resulting in dephosphorylation of tyrosines that control endocytosis in GluN2 NMDAR subunits. Adult hippocampal neurogenesis (AHN) that normally contributes to memory processes is also defective in the absence of NSPA.SummaryNSPA function is crucial in memory processes controlling the stability of NMDAR at PSD through the ubiquitination of PTPMEG/PTPN4 and also through AHN. As anti-P autoantibodies reproduce the impairments of glutamatergic transmission, plasticity and memory performance seen in the absence of NSPA, it might be expected to perturb the NSPA/PTPMEG/PTPN4 pathway leading to hypofunction of NMDAR. This neuropathogenic mechanism contrasts with that of anti-NMDAR antibodies also involved in lupus cognitive dysfunction. Testing this hypothesis might open new therapeutic possibilities for cognitive dysfunction in SLE patients bearing anti-P autoantibodies.
KW - N-Methyl-D-aspartic acid receptor
KW - PTPMEG/PTPN4
KW - antiribosomal P protein autoantibodies
KW - cognitive dysfunction
KW - glutamatergic synapsis
KW - neurogenesis
KW - systemic lupus erythematosus
KW - ubiquitin proteasomal system
UR - http://www.scopus.com/inward/record.url?scp=85131465152&partnerID=8YFLogxK
U2 - 10.1097/WCO.0000000000001054
DO - 10.1097/WCO.0000000000001054
M3 - Review article
C2 - 35674087
AN - SCOPUS:85131465152
SN - 1350-7540
VL - 35
SP - 436
EP - 442
JO - Current Opinion in Neurology
JF - Current Opinion in Neurology
IS - 3
ER -